Articaine

CHEMBL1093 Phase 4 Одобрено Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
284.4 g/mol
LogP
2.8
Phase
4

A local anesthetic belonging to the amide class that blocks sodium channels in nerve membranes, preventing pain signals from being transmitted to the brain. It is widely used in dental procedures and is noted for its ability to penetrate bone tissue effectively.

Молекулярная масса

284,3800 g/mol

LogP

2,80

TPSA

95,70 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Механизм действия

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

2D Структура

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC

InChI

InChI=1S/C13H20N2O3S/c1-5-6-14-9(3)12(16)15-10-8(2)7-19-11(10)13(17)18-4/h7,9,14H,5-6H2,1-4H3,(H,15,16)

Molecular Formula

C13H20N2O3S

HBD / HBA

2 / 5

Вращаемые Связи

7

Тяжёлые Атомы

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A local anesthetic belonging to the amide class that blocks sodium channels in nerve membranes, preventing pain signals from being transmitted to the brain. It is widely used in dental procedures and is noted for its ability to penetrate bone tissue effectively.

Blocks voltage-gated sodium channels in nerve cell membranes, preventing the generation and conduction of nerve impulses. This produces reversible loss of sensation in the area of application.

Yes, Articaine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1093. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 32170. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.